<DOC>
	<DOC>NCT01603342</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to determine the feasibility of demonstrating a quantifiable change from baseline in punch biopsy-induced bleeding durations and blood loss volumes in healthy subjects after receiving clopidogrel anti-platelet therapy.</brief_summary>
	<brief_title>A Pilot Study to Determine the Impact of Clopidogrel (PlavixÂ®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>PT within normal laboratory range The receipt of any investigational drug within 1 month prior to this trial Use of anticoagulation or antiplatelet therapydefined as vitamin K antagonists, platelet antagonists, heparin (or low molecular weight heparin), aspirin or NSAIDs within 30 days prior to trial AfricanAmerican race Weight above or equal to 160 kg Recent diagnosis of any illness that would be present concomitant to trial period</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>